Literature DB >> 8431360

Metabolism of the bioreductive cytotoxin SR 4233 by tumour cells: enzymatic studies.

J Wang1, K A Biedermann, C R Wolf, J M Brown.   

Abstract

SR 4233 (3-amino-1,2,4-benzotriazine 1,4-dioxide) is an anti-tumour agent that has a highly selective toxicity to hypoxic cells. In this study we delineate the role of several different bioreductive enzymes in the metabolism of SR 4233 by two tumour cell lines HT 1080 (human fibrosarcoma) and SCCVII (mouse carcinoma). Enzyme kinetics demonstrates similar KM of HT 1080 and SCCVII cell sonicates and differing Vmax. Among all cofactors tested, NADPH was the most important one in reducing SR 4233 by both tumour cell sonicates. NADH was the second most important cofactor while hypoxanthine and N-methylnicotinamide were less involved in the reduction of SR 4233. Carbon monoxide inhibited the reduction by about 60% suggesting that cytochrome P-450 may play a major role in the reduction of SR 4233 under hypoxia in both SCCVII and HT 1080 cells. DT diaphorase is also involved, particularly in HT 1080 cells, in this drug reduction. The level of functional cytochrome P-450, cytochrome P-450 reductase activity and DT diaphorase activity in both cell lines were assayed. These enzyme levels were all higher in SCCVII cells than in HT 1080 cells. This result correlated the higher Vmax of SR 4233 reduction in SCCVII cells than in HT 1080 cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8431360      PMCID: PMC1968170          DOI: 10.1038/bjc.1993.59

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  24 in total

1.  Repair of DNA and chromosome breaks in cells exposed to SR 4233 under hypoxia or to ionizing radiation.

Authors:  J Wang; K A Biedermann; J M Brown
Journal:  Cancer Res       Date:  1992-08-15       Impact factor: 12.701

2.  A general mechanism for microsomal activation of quinone anticancer agents to free radicals.

Authors:  N R Bachur; S L Gordon; M V Gee
Journal:  Cancer Res       Date:  1978-06       Impact factor: 12.701

3.  Adaptation of the bicinchoninic acid protein assay for use with microtiter plates and sucrose gradient fractions.

Authors:  M G Redinbaugh; R B Turley
Journal:  Anal Biochem       Date:  1986-03       Impact factor: 3.365

4.  A new method for simultaneous purification of cytochrome b5 and NADPH-cytochrome c reductase from rat liver microsomes.

Authors:  T Omura; S Takesue
Journal:  J Biochem       Date:  1970-02       Impact factor: 3.387

5.  Isolation of a high spin form of cytochrome P-450 induced in rat liver by 3-methylcholanthrene.

Authors:  C R Wolf; F Oesch
Journal:  Biochem Biophys Res Commun       Date:  1983-03-16       Impact factor: 3.575

Review 6.  Reductive drug metabolism.

Authors:  K E Mc Lane; J Fisher; K Ramakrishnan
Journal:  Drug Metab Rev       Date:  1983       Impact factor: 4.518

7.  A new highly sensitive assay for ethoxycoumarin deethylase in cultured hepatocytes.

Authors:  J De Graeve; P Kremers; C Frankinet; J Gielen
Journal:  Anal Biochem       Date:  1980-05-15       Impact factor: 3.365

Review 8.  Free radicals in pharmacology and toxicology--selected topics.

Authors:  R P Mason; C F Chignell
Journal:  Pharmacol Rev       Date:  1981-12       Impact factor: 25.468

9.  SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells.

Authors:  E M Zeman; J M Brown; M J Lemmon; V K Hirst; W W Lee
Journal:  Int J Radiat Oncol Biol Phys       Date:  1986-07       Impact factor: 7.038

10.  Enhancement of CCNU cytotoxicity by misonidazole: possible therapeutic gain.

Authors:  D G Hirst; J M Brown; J L Hazlehurst
Journal:  Br J Cancer       Date:  1982-07       Impact factor: 7.640

View more
  13 in total

1.  Discovery and optimization of benzotriazine di-N-oxides targeting replicating and nonreplicating Mycobacterium tuberculosis.

Authors:  Sidharth Chopra; Gary A Koolpe; Arlyn A Tambo-Ong; Karen N Matsuyama; Kenneth J Ryan; Tran B Tran; Rupa S Doppalapudi; Edward S Riccio; Lalitha V Iyer; Carol E Green; Baojie Wan; Scott G Franzblau; Peter B Madrid
Journal:  J Med Chem       Date:  2012-06-25       Impact factor: 7.446

2.  Improved potency of the hypoxic cytotoxin tirapazamine by DNA-targeting.

Authors:  Yvette M Delahoussaye; Michael P Hay; Frederik B Pruijn; William A Denny; J Martin Brown
Journal:  Biochem Pharmacol       Date:  2003-06-01       Impact factor: 5.858

3.  Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069.

Authors:  A V Patterson; M P Saunders; E C Chinje; D C Talbot; A L Harris; I J Strafford
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

4.  Does reductive metabolism predict response to tirapazamine (SR 4233) in human non-small-cell lung cancer cell lines?

Authors:  E C Chinje; A V Patterson; M P Saunders; S D Lockyer; A L Harris; I J Stratford
Journal:  Br J Cancer       Date:  1999-12       Impact factor: 7.640

5.  Systematic and Molecular Basis of the Antibacterial Action of Quinoxaline 1,4-Di-N-Oxides against Escherichia coli.

Authors:  Guyue Cheng; Bei Li; Chenxi Wang; Hongfei Zhang; Guixia Liang; Zhifei Weng; Haihong Hao; Xu Wang; Zhenli Liu; Menghong Dai; Yulian Wang; Zonghui Yuan
Journal:  PLoS One       Date:  2015-08-21       Impact factor: 3.240

Review 6.  The experimental development of bioreductive drugs and their role in cancer therapy.

Authors:  P Workman; I J Stratford
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

Review 7.  SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours.

Authors:  J M Brown
Journal:  Br J Cancer       Date:  1993-06       Impact factor: 7.640

8.  Detection of hypoxia by measurement of DNA damage in individual cells from spheroids and murine tumours exposed to bioreductive drugs. I. Tirapazamine.

Authors:  P L Olive
Journal:  Br J Cancer       Date:  1995-03       Impact factor: 7.640

9.  Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233).

Authors:  A V Patterson; H M Barham; E C Chinje; G E Adams; A L Harris; I J Stratford
Journal:  Br J Cancer       Date:  1995-11       Impact factor: 7.640

10.  Molecular mechanisms of tirapazamine (SR 4233, Win 59075)-induced hepatocyte toxicity under low oxygen concentrations.

Authors:  S Khan; P J O'Brien
Journal:  Br J Cancer       Date:  1995-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.